On October 20, 2020 Kadmon Holdings, Inc. (NYSE:KDMN) reported it will present preclinical data on its anti-PD-1/IL-15 fusion protein in development for oncology indications, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC 2020) 35th Anniversary Annual Meeting, taking place virtually November 9 – 14, 2020 (Press release, Kadmon, OCT 20, 2020, View Source [SID1234568696]).
Details of the presentation are outlined below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation

Title: A novel human anti-PD1/IL15 bi-functional protein with robust anti-tumor activity and low systemic toxicity

Category: Immune Stimulants and Immune Modulators

Times: Wednesday, November 11, 2020, 5:15-5:45 p.m. EST

Friday, November 13, 2020, 4:40-5:10 p.m. EST

Abstract ID: 573